ADC Therapeutics (ADCT) Payables (2019 - 2023)
Historic Payables for ADC Therapeutics (ADCT) over the last 5 years, with Q3 2023 value amounting to $9.0 million.
- ADC Therapeutics' Payables fell 2268.54% to $9.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was $9.0 million, marking a year-over-year decrease of 2268.54%. This contributed to the annual value of $12.4 million for FY2022, which is N/A changed from last year.
- Per ADC Therapeutics' latest filing, its Payables stood at $9.0 million for Q3 2023, which was down 2268.54% from $11.7 million recorded in Q2 2023.
- ADC Therapeutics' 5-year Payables high stood at $16.5 million for Q1 2022, and its period low was $3329.0 during Q4 2019.
- Its 5-year average for Payables is $9.3 million, with a median of $11.6 million in 2022.
- In the last 5 years, ADC Therapeutics' Payables surged by 21515673.09% in 2021 and then plummeted by 4715.86% in 2023.
- ADC Therapeutics' Payables (Quarter) stood at $3329.0 in 2019, then skyrocketed by 84.62% to $6146.0 in 2020, then soared by 195604.52% to $12.0 million in 2021, then rose by 2.69% to $12.4 million in 2022, then decreased by 27.32% to $9.0 million in 2023.
- Its Payables stands at $9.0 million for Q3 2023, versus $11.7 million for Q2 2023 and $8.7 million for Q1 2023.